Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-77242113 for plaque psoriasis involving special areas
ISRCTN54453452Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Peptides
01
Overview
Phase 3, randomised trial in plaque psoriasis comparing JNJ-77242113 with Placebo then JNJ-77242113 (2 arms). Primary endpoint: Percentage of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1 and at least 2-grade improvement from baseline at Week 16. Started Oct 2023; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ISRCTN54453452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54453452.